Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a clinical-stage company chasing a niche but meaningful anticoagulation market, and its shares drifted modestly lower in early September 2026. Fresh off a second-quarter update and an FDA-endorsed path into late-stage development, the micro-cap has been reshaping its story …
A medical-device company built around a single flagship therapy is only as strong as its commercial execution, and 2026 has tested that reality for CVRx. Shares of CVRx, Inc (NASDAQ: CVRX) have slipped toward the low end of their 52-week range after a second …
● Consistent with the auto-generated framing, there is no single verified catalyst behind the "steady" characterization.
Dare Bioscience, Inc. (NASDAQ:DARE) has quietly turned into one of the more active names in women's health this summer, even as its shares trade below a dollar. The Nasdaq-listed company, ticker DARE, spent August 2026 stacking up developments: a fresh federal research grant, new …
A quiet uptick in Citius Oncology, Inc (NASDAQ:CTOR) shares belies a more interesting story unfolding beneath the surface: the commercial ramp of an FDA-approved lymphoma therapy. The small-cap oncology company, majority owned by Citius Pharmaceuticals, is roughly a year into launching its lead product …
A blood-purification pioneer with a commercial product in Europe and a long-sought U.S. approval still in reach, CytoSorbents Corporation (NASDAQ: CTSO) has become a study in how hard the last mile of regulatory access can be. Another single-session slide has drawn fresh attention to …
● The small daily decline in CMPX shares has no single identifiable public catalyst and is consistent with routineVolatilityin a pre-commercial biotech.
● The framing points to a plunge, but there is no identifiable public catalyst behind the quoted move.
● CONMED occupies a corner of the medical-device world that rarely grabs headlines but quietly touches thousands of operating rooms every day.
Few small-cap biotechs enter aTrading sessioncarrying a brand-new name, and that is exactly where Cerenome, Inc. (NASDAQ:CNSY) finds itself. The company that used to trade as Plus Therapeutics adopted its new identity only weeks ago, and the shares have been choppy ever since. A …